🇺🇸 FDA
Pipeline program

QVA149

CQVA149A2336

Phase 3 small_molecule completed

Quick answer

QVA149 for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials